Treatment of psoriasis with anti-TNF drugs during pregnancy: Case report and review of the literature

Dermatology

Volumn 220, Issue 1, 2010, Pages 71-76

  Puig, Lluís ^a   Barco, Didac ^a   Alomar, Agustín ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Breastfeeding; Generalized pustular psoriasis of pregnancy; Impetigo herpetiformis; Infliximab; Pregnancy; Psoriasis

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; LUPUS ANTICOAGULANT; PREDNISONE; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CASE REPORT; CESAREAN SECTION; DELIVERY; DISEASE SEVERITY; FEMALE; HUMAN; IMPETIGO HERPETIFORMIS; MAINTENANCE THERAPY; MEDICAL LITERATURE; PREGNANCY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; CYCLOSPORINE; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PSORIASIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTORS;

EID: 76649111042     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000262284     Document Type: Article

References (32)

1. Weatherhead S, Robson SC, Reynolds NJ: Management of psoriasis in pregnancy. BMJ 2007; 334: 1218-1220.
2. Ben-David G, Sheiner E, Hallak M, Levy A: Pregnancy outcome in women with psoriasis. J Reprod Med 2008; 53: 183-187.
3. Lam J, Polifka JE, Dohil MA: Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008; 59: 295-315.
4. Chambers CD, Tutuncu ZN, Johnson D, Jones KL: Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther 2006; 8: 215.
5. Sheth N, Greenblatt DT, Acland K, Barker J, Teixeira F: Generalized pustular psoriasis of pregnancy treated with infliximab. Clin Exp Dermatol 2009; 34: 521-522.
6. Cush JJ: Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis 2005; 64(suppl 4):iv18-iv23.
7. Berthelot JM, De Bandt M, Goupille P, Solau- Gervais E, Lioté F, Goeb V, et al: CRI (Club Rhumatismes et Inflammation): exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 2009; 76: 28-34.
8. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR: Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99: 2385-2392.
9. Carter JD, Valeriano J, Vasey FB: Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. J Rheumatol 2006; 33: 1014-1017.
10. Chakravarty EF, Sanchez-Yamamoto D, Bush TM: The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003; 30: 241-246.
11. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB: A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009; 36: 635-641.
12. Koren G, Inoue M: Do tumor necrosis factor inhibitors cause malformations in humans? J Rheumatol 2009; 36: 465-466.
13. Lichtenstein GR, Cohen RD, Feagan BG, Sandhorn WJ, Salzberg BA, Chen DM, et al: Safety of infliximab in Crohn's disease: data from the 5,000-patient TREAT registry. Gastroenterology 2004; 126(suppl 2):A54.
14. Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, et al: Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005; 21: 733-738.
15. O'Donnell S, O'Morain C: Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment Pharmacol Ther 2008; 27: 885-894.
16. Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register: Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum 2006; 54: 2701-2702.
17. Roux CH, Brocq O, Breuil V, Albert C, Euller- Ziegler L: Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007; 46: 695-698.
18. Rosner I, Haddad A, Boulman N, Feld J, Avshovich N, Slobodin G, et al: Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007; 46: 1508.
19. Simister NE: Placental transport of immunoglobulin G. Vaccine 2003; 21: 3365-3369.
20. Kane S, Ford J, Cohen R, Wagner C: Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 2009; 43: 613-616.
21. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC: Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006; 4: 1255-1258.
22. Mahadevan U, Terdiman JP, Church J, Vasiliauskas E, Gitis A, Dubinsky MC: Infliximab levels in infants born to women with inflammatory bowel disease. Gastroenterology 2007; 132(suppl 2):A144.
23. Martin PL, Cornacoff JB, Treacy G, Eirikas E, Marini J, White KL Jr, et al: Effects of administration of a monoclonal antibody against mouse tumor necrosis factor alpha during pregnancy and lactation on the preand postnatal development of the mouse immune system. Int J Toxicol 2008; 27: 341-347.
24. Martin PL, Oneda S, Treacy G: Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. Am J Reprod Immunol 2007; 58: 138-149.
25. Mottet C, Juillerat P, Pittet V, Gonvers JJ, Froehlich F, Vader JP, et al: Pregnancy and breastfeeding in patients with Crohn's disease. Digestion 2007; 76: 149-160.
26. Stengel JZ, Arnold HL: Is infliximab safe to use while breastfeeding? World J Gastroenterol 2008; 14: 3085-3087.
27. Wang W, Wang EQ, Balthasar JP: Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84: 548-558.
28. Ostensen M, Eigenmann GO: Etanercept in breast milk. J Rheumatol 2004; 31: 1017-1018.
29. Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA: Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008; 22: 847-861.
30. Remicade Summary of Product Characteristics (EMEA). www.emea.europa.eu/ humandocs/ Humans/EPAR/remicade/remicade. htm.
31. Reich K, Griffiths C, Barker J, Chimenti S, Daudén E, Giannetti A, et al: Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology 2008; 217: 268-275.
32. Skomsvoll JF, Wallenius M, Koksvik HS, Rødevand E, Salvesen KA, Spigset O, et al: Drug insight: anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation. Nat Clin Pract Rheumatol 2007; 3: 156-164.